Awakn Life Sciences CorpCanadian Securities Exchange:AWKNView on OTCQB
- LAST PRICE0.1200
- TODAY'S CHANGE (%)0.0100 (9.0909%)
- Bid / Lots0.1200/ 6
- Ask / Lots0.1350/ 14
- Open / Previous Close0.1100 / 0.1100
- Day Range
- 52 Week Range
- Volume26,800
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AWKN |
|---|---|---|
| 09:32 ET | 1500 | 0.11 |
| 09:57 ET | 1000 | 0.13 |
| 11:27 ET | 2000 | 0.135 |
| 12:08 ET | 3500 | 0.135 |
| 12:46 ET | 9500 | 0.135 |
| 12:51 ET | 1000 | 0.12 |
| 01:26 ET | 7000 | 0.12 |
| 01:29 ET | 1000 | 0.12 |
Oct 22, 2024
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites, from 7:32AM ET on Tuesday Oct 22, 2024 by Dow Jones
7:32AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 15, 2024
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program, from 7:32AM ET on Tuesday Oct 15, 2024 by Dow Jones
7:32AM ET on Tuesday Oct 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Awakn Life Sciences Corp | 4.6M | -1.3x | --- |
Asep Medical Holdings Inc | 4.5M | -0.7x | --- |
Quest Pharmatech Inc | 5.1M | 0.4x | --- |
Marvel Biosciences Corp | 6.3M | -2.6x | --- |
CVR Medical Corp | 2.0M | -0.6x | --- |
Nirvana Life Sciences Inc | 2.5M | -2.3x | --- |
Company Information
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe and through licensing partners. The Company operates in Ireland and Canada. The Company’s development pipeline includes AWKN-001, AWKN-002 and MDMA.
Contact Information
- Headquarters
- 301-217 Queen St WestTORONTO, ON, Canada M5V 0R2
- Phone
- 416-907-5644
- Fax
- ---
Executives
- Independent Chairman of the Board
- George Scorsis
- President, Chief Executive Officer, Director
- Anthony Tennyson
- Chief Financial Officer
- Katherine Butler
- Chief Operating Officer
- James Collins
- Chief Scientific Officer
- Shaun Mcnulty
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6M |
|---|---|
Revenue (TTM) | $82.4K |
Shares Outstanding | 41.7M |
Awakn Life Sciences Corp does not pay a dividend. | |
Beta | --- |
EPS | $-0.09 |
Book Value | $-0.04 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 55.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,183.22% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
